News
This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...
HealthDay on MSN8h
FDA Approves Empaveli for Rare Kidney DiseasesThe U.S. Food and Drug Administration has approved Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback